Top Markets
#1 ADO Protocol ADO Protocol +336.33%
#2 Islamic Coin Islamic Coin +155.40%
#3 GoPlus Security GoPlus Security +51.61%
#4 Starpower Starpower +33.70%
#5 GAIB AID GAIB AID +24.67%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.27%
#7 The Black Bull The Black Bull +15.49%
#8 Nockchain Nockchain +14.55%
#9 XMAQUINA XMAQUINA +12.20%
#10 Casper Network Casper Network +11.65%
Coin of the day
ADO Protocol ADO Protocol
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Classement en actions #33297
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Prix de l'action
$0.4264
Dernière synchronisation: 2022-09-14
Capitalisation boursière
$7.93M
Changement (1 jour)
-16.44%
Changement (1 an)
0.00%
Pays
US
Échange Caladrius Biosciences, Inc. (CLBS)

Catégorie

Healthcare
Bénéfices pour Caladrius Biosciences, Inc. (CLBS)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Caladrius Biosciences, Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Caladrius Biosciences, Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE